RSL3, a potent ferroptosis inducer, has gained considerable attention in prostate cancer treatment due to its ability to selectively kill cancer cells by targeting the glutathione peroxidase 4 (GPX4) pathway.34 Given our previous findings that AR inhibition enhances sensitivity to ferroptosis via the LTFe-LTF axis, we investigated whether combining RSL3 with the AR antagonist ENZ could provide a more effective therapeutic approach against both hormone-sensitive prostate cancer (HSPC) and CRPC. The gene discussed is AR; the disease is prostate carcinoma.